|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 9/127 | |
| C12N 15/88 | |||
| C12N 15/113 | |||
| A61K 48/00 |
| (11) | Patento numeris | 2994167 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 14795153.7 |
| Europos patento paraiškos padavimo data | 2014-05-06 | |
| (97) | Europos patento paraiškos paskelbimo data | 2016-03-16 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-05-06 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2014/036915 |
| Data | 2014-05-06 |
| (87) | Numeris | WO 2014/182661 |
| Data | 2014-11-13 |
| (30) | Numeris | Data | Šalis |
| 201361820036 P | 2013-05-06 | US |
| (72) |
KASPERKOVITZ, Pia, US
GOLLOB, Jared, US
|
| (73) |
Alnylam Pharmaceuticals, Inc.,
300 Third Street, 3rd Floor, Cambridge, MA 02142,
US
|
| (54) | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES |
| DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES |